US Pharm. 2015;40(12):6.

Silver Spring, MD—The FDA recently approved three new drugs for the treatment of multiple myeloma in patients who have received previous therapies. Daratumumab (Darzalex; Janssen Biotech) is the first monoclonal antibody approved to treat patients with multiple myeloma who have received at least three prior treatments. Ixazomib (Ninlaro; Takeda Pharmaceuticals), the first oral proteasome inhibitor, is approved in combination with lenalidomide, an older multiple myeloma drug, and the corticosteroid dexamethasone. Elotuzumab (Empliciti; Bristol-Myers Squibb Company) is the second monoclonal antibody approved for multiple myeloma, and it also must be used in combination with lenalidomide and dexamethasone. These agents represent important new options for treatment and add to the growing roster of therapies for this hematologic malignancy.

To comment on this article, contact